What Does Organogenesis (ORGO) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Summary
Organogenesis (ORGO) is an advanced wound care and regenerative medicine company targeting chronic wounds such as diabetic foot ulcers. As a healthcare stock, its revenue, earnings outlook, and share-price trajectory are driven by Medicare reimbursement policy changes and product portfolio growth.
Subscribe🏢 What kind of company is Organogenesis?
Organogenesis (ORGO) is a regenerative-medicine-focused healthcare company headquartered in the United States. It develops, manufactures, and markets bioengineered regenerative products that support the healing of damaged skin and soft tissue, and has built a clinically validated portfolio in advanced wound care and surgical applications.
The company operates a single regenerative-medicine segment covering advanced wound care products for chronic wounds such as diabetic foot ulcers, surgical regenerative solutions, and sports-medicine products. Its clinically backed product lines, including the Apligraf and PuraPly families, form the core of the business.
💰 How does Organogenesis make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| Advanced Wound Care | Core | Skin-substitute and regenerative products for chronic wounds such as diabetic foot ulcers |
| Surgical | Key Growth Driver | Regenerative solutions for surgical-site management |
Advanced wound care products account for the bulk of revenue, while surgical and sports-medicine products provide portfolio diversification. The business model is highly sensitive to changes in product pricing and reimbursement policy, producing an alternating cycle of growth and adjustment depending on the policy environment. Given the single regenerative-medicine segment, prescription and adoption trends for core products are directly reflected in revenue and margins, and the expansion of new products is the key driver of a profitability recovery.
📐 Organogenesis Market Cap and Company Scale
Market capitalization stands at $191.7M, with 854 people employees.
The company is a mid-cap healthcare name in the regenerative-medicine and advanced wound care space, grouped alongside other regenerative-medicine and cell-therapy peers such as MDXG and VCEL. It has built cash-generating capability based on clinical evidence and a specialized sales network in the wound care market, and its valuation tends to swing meaningfully with shifts in the reimbursement environment.
📈 Organogenesis Outlook and Share-Price Trends
1-Year Price Performance
Analyst Consensus
52-Week Price RangeRising chronic wound care demand driven by population aging and the growing diabetic population is the medium- to long-term growth driver. Portfolio expansion into surgical and sports medicine, along with the accumulation of new clinical evidence, also serves as a growth engine. Over the near term, however, changes to public-insurance reimbursement and pricing policies, including Medicare, can introduce meaningful volatility into revenue. Intensifying competition from other regenerative-medicine names such as MDXG, VCEL, and HUMA, as well as delays in clinical and regulatory timelines, can also act as potential volatility factors.
- Expanding chronic wound care demand
- Portfolio expansion into surgical and sports medicine
- Adoption growth through clinical-evidence accumulation
⚔️ Organogenesis Core Competitive Strengths and Risks
A clinically validated regenerative-medicine portfolio and sales network are strengths, while revenue volatility stemming from reimbursement policy changes is the key risk.
💪 Core Competitive Strengths
⚠️ Core Risks
Direct competitors grouped within the same healthcare sector include MDXG in amnion and regenerative medicine, VCEL in cell-therapy-based skin regeneration, HUMA in bioengineered tissue, and MESO in regenerative-medicine cell therapy. Related names in adjacent regenerative-medicine and transplant themes include AXGN in nerve regeneration and TMDX in organ transplant preservation solutions.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 MDXG | Mimedx Group Inc | $4.57 | -0.7% | $666.1M | 116.0 | 3.1 | 2.88% | - |
 VCEL | Vericel Corp | $38.30 | +1.1% | $2.0B | 82.9 | 5.3 | 7.16% | - |
 HUMA | Humacyte Inc | $0.57 | +0.1% | $157.7M | - | 5.0 | -547.87% | - |
 MESO | Mesoblast Ltd ADR | $15.48 | -0.1% | $2.0B | - | 3.5 | -9.89% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 AXGN | Axogen Inc | $42.16 | +0.7% | $2.3B | - | 8.8 | -18.21% | - |
 TMDX | Transmedics Group Inc | $82.18 | -3.4% | $2.8B | 21.4 | 5.5 | 36.28% | - |
✅ Organogenesis Investor Checklist
Key items to review when considering an investment in Organogenesis. Changes to public-insurance reimbursement and pricing policy are the most important near-term variable, and product portfolio expansion, new clinical-evidence accumulation, and shifts in the competitive environment should also be monitored.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 💵 Reimbursement Pricing | Trends in public-insurance (e.g., Medicare) reimbursement and pricing policy | Phase of Heightened Volatility |
| 📈 Product Adoption | Prescription trends for core wound care products and expansion of new products | Monitoring Required |
| 🔬 Clinical Evidence | Label expansion and accumulation of new clinical data | Expanding Trend |
| 📉 Profitability | Margin and capital-efficiency trends | Varies with Policy Environment |
Changes in public-insurance pricing policy can place significant pressure on revenue and profitability in the near term. Given the single regenerative-medicine segment, dependence on core products is high, and intensifying competition in regenerative medicine, along with clinical and regulatory timeline delays, can act as share-price volatility drivers.
Organogenesis is a mid-cap healthcare name with a clinically validated portfolio in regenerative medicine and advanced wound care. Because the stock is highly sensitive to changes in reimbursement policy, a phased buying approach with a long-term perspective is recommended.
Subscribe Today's 5 AI picks, all free